Organic compounds -- part of the class 532-570 series inventions 12/06

20060293519 - Method for producing cyclic diamine derivative or salt thereof: (wherein Ar represents a phenyl group, a pyridyl group, or a pyrimidinyl group, any of which may have a substituent; X represents NH, S, or O; ring A represents a benzene ring or a pyridine ring, which may have a substituent; 1 represents an integer of 1 or 2; m... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060293520 - Mehtod for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils: h

20060293521 - Cationic surfactants:

20060287523 - Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc): This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diaminophenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order:... Agent: Nixon & Vanderhye, PC

20060287524 - Nile red luminescent compound emitting red light, process for producing the same and luminescence element utilizing the same: The objectives of this invention are to provide a novel Nile red luminescent compound capable of emitting red light at a high luminance and at high color purity, and a luminescence element capable of emitting light at a high luminance. To achieve these objectives, the present invention provides a Nile... Agent: Rader Fishman & Grauer PLLC

20060287525 - Aromatic prodrugs of propofol, compositions and uses thereof: Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting are disclosed herein.... Agent: Richard F. Trecartin Dorsey & Whitney LLP

20060287526 - Compositions and methods pertaining to pna synthons and oligomers comprising a universal base: This invention is related to compositions and methods pertaining to PNA synthons, PNA oligomers and/or PNA/DNA Chimeras comprising a universal base.... Agent: Applied Biosystems

20060287527 - Process for producing acrylic acid derivative: Processes for producing a compound represented by the formula (1), which includes an acrylic acid derivative and is useful as an agricultural chemical or medicine. One of the processes comprises the step of formulating a compound (3) and converting the OH of the resultant compound (2) into OR″. The first... Agent: Lahive & Cockfield

20060287528 - Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor: The present invention relates to crystalline anhydrate polymorphs of the dihydrogenphosphate salt of (2R)4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H) yl]-1-(2,4,5-trifluorophenyl)butan-2-amine as well as a process for their preparation, pharmaceutical compositions containing these novel forms, and methods of use of the novel forms and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood pressure.... Agent: Merck And Co., Inc

20060281919 - Processs for preparing triazine compounds: A process for preparing a triazine compound represented by formula (1) including reacting a 2,4,6-trichlorotriazine, in the presence of a base, with a compound represented by the formula (2) in an organic solvent containing water and an aromatic hydrocarbon is provided.... Agent: Sughrue Mion, PLLC

20060281920 - Derivatives of hydroxamic acid as metalloproteinase inhibitors: Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma: formula (I) wherein Ar represents an optionally substituted aryl, heteroaryl, C3-C8 cycloalkyl or heterocycloakyl group; R represents hydrogen or C1-C6 alkyl, or C3-C6... Agent: Banner & Witcoff

20060281921 - A2b adenosine receptor antagonists: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.... Agent: Brian Lewis Cv Therapeutics, Inc.

20060276643 - Amine-substituted diphenyldiphosphines: P

20060276644 - Process for the production of isocyanatosilane and silylisocyanurate: A process is provided for the production of isocyanatosilane from silylorganocarbamate in a cracking zone with a predetermined portion of purged reaction medium undergoing conversion in a trimerization zone to silylisocyanurate....

20060276645 - novel carboxylic acid derivatives, their preparation and use: p

20060276646 - 6-alkoxy-pyrido-pyrimidines:

20060276647 - Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one: A process comprising a reaction of ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate with a formic acid compound in the presence of an ammonium carboxylate gives 6,7-bis(2-methoxyethoxy)quinazolin-4-one in a high yield....

20060276648 - Fluorine-containing amide compound and method for preparing the same: p

20060276649 - Method for producing ethylene-amines: Process for the preparation of ethylenamines, in particular diethylenetriamine (DETA), by continuous reaction of ethylenediamine (EDA) in the presence of a heterogeneous catalyst, where the reaction is carried out in a reaction column....

20060276650 - Pyrazole compounds: Compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are suitable as ligands of 5 HT receptors....